IQV vs. ONC: IQVIA vs. BeOne Medicines Stock Comparison

Company Profile

IQVIA (IQV) and BeOne Medicines (ONC) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but IQV is classified in Life Sciences Tools & Services while ONC is classified in Biotechnology.

IQVIA (IQV) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both IQVIA (IQV) at 21.39% and BeOne Medicines (ONC) at 18.40% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both IQVIA (IQV) at 8.05% and BeOne Medicines (ONC) at 13.86% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

BeOne Medicines (ONC) at 22.15% operates in the top operating margin quartile, ahead of IQVIA (IQV) at 13.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both IQVIA (IQV) at 5.87% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: IQVIA (IQV) reports EPS growth of 4.67%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while IQVIA (IQV) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for IQV.

BeOne Medicines (ONC) at 0.35 is near its industry mid-range for debt-to-equity ratio, while IQVIA (IQV) at 2.40 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither IQVIA (IQV) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither IQVIA (IQV) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

IQVIA (IQV) at 33.07 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.

IQVIA (IQV) at 2.59 sits in the cheaper P/S ratio quartile while BeOne Medicines (ONC) at 7.04 prices around its industry’s middle — IQV costs less per dollar of sales, though read it alongside growth and margins.

Both IQVIA (IQV) at 6.73 and BeOne Medicines (ONC) at 7.98 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics